Bitter Melon (Momordica Charantia): Antimicrobial and Anti-Inflammatory Effects

Momordica charantia, commonly known as bitter gourd or bitter melon, is a medicinal plant belonging to the Cucurbitaceae family. Widely consumed as a vegetable in tropical and subtropical regions, it has also been used in traditional medicine for various health conditions. Beyond its nutritional value, the plant has attracted scientific interest because of its potential antimicrobial, anti-inflammatory, antioxidant, and immunomodulatory properties. These biological effects are associated with several phytochemicals present in its fruits, leaves, seeds, and other plant parts. ¹ 

Phytochemical composition 

The pharmacological properties of M. charantia are attributed to a diverse range of bioactive compounds, including flavonoids, phenolic compounds, triterpenoids, saponins, polysaccharides, sterols, and proteins or peptides. The composition varies according to the plant part, growing conditions, and extraction method. 

• Flavonoids and phenolic compounds: Contribute to antioxidant activity and may modulate inflammatory pathways 

• Triterpenoids and saponins: Have been investigated for their antimicrobial, anti-inflammatory, and metabolic effects 

• Bioactive proteins and peptides: Certain isolated compounds have demonstrated biological activity against microorganisms or immune-related targets in experimental studies 

• Polysaccharides: May influence antioxidant responses and immune regulation 

The combined effects of these constituents may contribute to the plant's biological activity, although the contribution of individual compounds and their interactions remain under investigation.² 

Antimicrobial effects of momordica charantia 

The antimicrobial potential of M. charantia has been investigated against different bacterial and fungal organisms. Extracts prepared from its fruits, leaves, seeds, and other parts have demonstrated varying degrees of antimicrobial activity.³ The plant contains compounds capable of interfering with microbial growth and survival.

Antibacterial activity: 

M. charantia extracts has antimicrobial effect against selected Gram-positive and Gram-negative bacteria. The degree of inhibition depends on the bacterial species, extract concentration, solvent used, and phytochemical composition. 

Proposed mechanisms include: 

• Disruption of microbial membranes: Certain plant constituents may affect membrane integrity and permeability, potentially causing leakage of cellular contents 

• Inhibition of microbial enzymes: Bioactive compounds may interfere with enzymes and metabolic processes required for bacterial growth 

• Interference with cellular functions: Some constituents may affect microbial protein synthesis and other essential cellular processes 

Antifungal and antiviral potential: 

Certain extracts and isolated proteins have demonstrated biological activity in experimental systems. However, these findings vary considerably depending on the preparation and the organism studied. 

The antiviral activity of specific plant-derived proteins is of particular research interest, but laboratory findings should not be interpreted as evidence that bitter gourd can prevent or cure viral infections. Similarly, its potential antifungal effects require further evaluation before therapeutic applications can be established.

Anti-inflammatory effects of Momordica charantia 

Inflammation is a protective biological response to infection, tissue injury, and other harmful stimuli. When inflammatory responses become excessive or persistent, they may contribute to tissue damage and chronic disease. M. charantia has been investigated for its potential to regulate inflammatory processes through antioxidant activity, cytokine modulation, and changes in intracellular signalling pathways. 

Modulation of inflammatory signalling: 

Experimental studies suggest that M. charantia extracts and their bioactive constituents may influence pathways involved in the production of inflammatory mediators. 

• NF-κB pathway: Inhibition of nuclear factor kappa B (NF-κB) signalling may reduce the expression of genes involved in inflammation 

• MAPK pathway: Modulation of mitogen-activated protein kinase (MAPK) signalling may influence inflammatory responses and cellular stress 

• TAK1 signalling: Experimental research in murine macrophages has investigated suppression of transforming growth factor-beta-activated kinase 1 (TAK1), a regulator of inflammatory signalling 

These pathways help explain the anti-inflammatory potential observed in preclinical studies, but their clinical relevance in humans remains uncertain.

Reduction of pro-inflammatory mediators: 

Certain experimental models have reported reduced production or expression of inflammatory mediators following exposure to M. charantia extracts or isolated constituents. These mediators include tumour necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), nitric oxide, and enzymes involved in inflammatory responses. 

The inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) pathways are also relevant targets in research on plant-derived anti-inflammatory compounds. Modulation of these mediators may help explain the effects observed in cell and animal studies. Nevertheless, results can differ across experimental models, and the findings do not establish a clinically effective anti-inflammatory treatment.

Antioxidant activity and inflammation: 

Oxidative stress occurs when the production of reactive oxygen species exceeds the body's antioxidant defences. Excessive oxidative stress can activate inflammatory signalling and contribute to cellular injury.⁴ 

The phenolic compounds and flavonoids present in M. charantia have demonstrated antioxidant activity in experimental research. By influencing oxidative processes, these compounds may indirectly affect inflammatory responses. Antioxidant and anti-inflammatory effects are therefore potentially interconnected, although their magnitude depends on the specific extract, dose, and biological model. 

Conclusion 

Momordica charantia is a nutritionally valuable plant with promising experimental antimicrobial and anti-inflammatory properties. Its phytochemicals may interfere with microbial growth, modulate NF-κB, MAPK, and TAK1 signalling, reduce selected inflammatory mediators, and influence oxidative stress. These findings provide a scientific rationale for continued pharmacological research. However, the available evidence is predominantly preclinical, and further clinical studies are required to establish safety, effective dosing, and therapeutic benefit in humans. Until stronger evidence is available, M. charantia should be regarded as a potential source of bioactive compounds rather than a proven treatment for infections or inflammatory diseases. 

Reference: 

1. Bortolotti M, Mercatelli D, Polito L. Momordica charantia, a Nutraceutical Approach for Inflammatory Related Diseases. Front Pharmacol. 2019;10:486. Published 2019 May 8. doi:10.3389/fphar.2019.00486 https://pmc.ncbi.nlm.nih.gov/articles/PMC6517695/

2. Wang S, Liu Q, Zeng T, et al. Immunomodulatory effects and associated mechanisms of Momordica charantia and its phytochemicals. Food Funct. 2022;13(23):11986-11998. Published 2022 Nov 28. doi:10.1039/d2fo02096c https://pubmed.ncbi.nlm.nih.gov/36350105/

3. Muribeca AJB, Gomes PWP, Paes SS, et al. Antibacterial Activity from Momordica charantia L. Leaves and Flavones Enriched Phase. Pharmaceutics. 2022;14(9):1796. Published 2022 Aug 26. doi:10.3390/pharmaceutics14091796 https://pmc.ncbi.nlm.nih.gov/articles/PMC9505480/

4. Jia S, Shen M, Zhang F, Xie J. Recent Advances in Momordica charantia: Functional Components and Biological Activities. Int J Mol Sci. 2017;18(12):2555. Published 2017 Nov 28. doi:10.3390/ijms18122555 https://pmc.ncbi.nlm.nih.gov/articles/PMC5751158/